Search research articles
Contact Us
Filters
Showing results (1481-1490 of 1,773) with videos related to
Page
of 178
Sort By:
Breast (Edinburgh, Scotland)
|
March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, et al.
Biorxiv : the Preprint Server for Biology
|
April 15, 2026
A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformation
Huihui Mou, Bo Gao, Gang Ye, et al.
Cell
|
July 2, 2025
Development of clinically viable non-muscle myosin II small molecule inhibitors
Laszlo Radnai, Erica J Young, Carlos Kikuti, et al.
American Journal of Human Genetics
|
May 21, 2019
The Genomic Medicine Integrative Research Framework: A Conceptual Framework for Conducting Genomic Medicine Research
Carol R Horowitz, Lori A Orlando, Anne M Slavotinek, et al.
Cancer Discovery
|
September 2, 2025
Defining the antitumor mechanism of action of a clinical-stage compound as a selective degrader of the nuclear pore complex
Linjie Yuan, Wenzhi Ji, Brendan G Dwyer, et al.
Nature
|
March 5, 2025
A cryptic pocket in CB1 drives peripheral and functional selectivity
Vipin Ashok Rangari, Evan S O'Brien, Alexander S Powers, et al.
British Journal of Cancer
|
October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
H M Earl, L Hiller, J A Dunn, et al.
Breast Cancer Research : BCR
|
January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A DeMichele, A C Dueck, D Hlauschek, et al.
ESMO Open
|
May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
F Penault-Llorca, F Dalenc, S Chabaud, et al.
Journal of the American Society of Nephrology : JASN
|
September 12, 2020
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)
Nigel D Toussaint, Eugenia Pedagogos, Nicole M Lioufas, et al.
Page
of 178
Search research articles
Search
Showing results (1481-1490 of 1,773) with videos related to
Sort By:
Page
of 178
Breast (Edinburgh, Scotland)
|
March 20, 2012
1st International consensus guidelines for advanced breast cancer (ABC 1)
F Cardoso, A Costa, L Norton, et al.
Biorxiv : the Preprint Server for Biology
|
April 15, 2026
A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformation
Huihui Mou, Bo Gao, Gang Ye, et al.
Cell
|
July 2, 2025
Development of clinically viable non-muscle myosin II small molecule inhibitors
Laszlo Radnai, Erica J Young, Carlos Kikuti, et al.
American Journal of Human Genetics
|
May 21, 2019
The Genomic Medicine Integrative Research Framework: A Conceptual Framework for Conducting Genomic Medicine Research
Carol R Horowitz, Lori A Orlando, Anne M Slavotinek, et al.
Cancer Discovery
|
September 2, 2025
Defining the antitumor mechanism of action of a clinical-stage compound as a selective degrader of the nuclear pore complex
Linjie Yuan, Wenzhi Ji, Brendan G Dwyer, et al.
Nature
|
March 5, 2025
A cryptic pocket in CB1 drives peripheral and functional selectivity
Vipin Ashok Rangari, Evan S O'Brien, Alexander S Powers, et al.
British Journal of Cancer
|
October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
H M Earl, L Hiller, J A Dunn, et al.
Breast Cancer Research : BCR
|
January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A DeMichele, A C Dueck, D Hlauschek, et al.
ESMO Open
|
May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
F Penault-Llorca, F Dalenc, S Chabaud, et al.
Journal of the American Society of Nephrology : JASN
|
September 12, 2020
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)
Nigel D Toussaint, Eugenia Pedagogos, Nicole M Lioufas, et al.
Page
of 178